> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Panel to Review Novartis Leukemia Therapy
- URL: https://www.fdaweb.com/oncologic-panel-to-review-novartis-leukemia-therapy/
- Published: 2017-06-08T12:00:00.000Z
- Updated: 2026-09-14T22:28:19.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138888

*Federal Register* notice: FDA has announced a 7/12 Oncologic Drugs Advisory Committee meeting. The panel intends to discuss a Novartis BLA for tisagenlecleucel-T suspension for intravenous use and indicated for treating pediatric and young adult patients three to 25 years of age with relapsed/refractory B-cell acute lymphoblastic leukemia. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-06-07/pdf/2017-11818.pdf?ref=fdaweb.com).